Daniel Meibom

Wuppertal, NW 42113, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability.

Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability.

Journal: ACS medicinal chemistry letters
Published: February 05, 2025

Impact of Linker Composition on VHL PROTAC Cell Permeability.

Impact of Linker Composition on VHL PROTAC Cell Permeability.

Journal: Journal of medicinal chemistry
Published: December 18, 2024

BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor.

BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor.

Journal: Journal of medicinal chemistry
Published: February 13, 2024

Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.

Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.

Journal: Journal of medicinal chemistry
Published: September 05, 2023

BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α2B Antagonist.

BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α2B Antagonist.

Journal: Journal of medicinal chemistry
Published: March 18, 2023

BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.

BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.

Journal: Journal of medicinal chemistry
Published: December 08, 2022

Linker-Dependent Folding Rationalizes PROTAC Cell Permeability.

Linker-Dependent Folding Rationalizes PROTAC Cell Permeability.

Journal: Journal of medicinal chemistry
Published: September 28, 2022

Solution Conformations Shed Light on PROTAC Cell Permeability.

Solution Conformations Shed Light on PROTAC Cell Permeability.

Journal: ACS medicinal chemistry letters
Published: October 16, 2020

Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Journal: Journal of medicinal chemistry
Published: September 24, 2020

Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure.

Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure.

Journal: European journal of medicinal chemistry
Published: September 27, 2018

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases.

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases.

Journal: ChemMedChem
Published: March 07, 2017

Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model.

Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model.

Journal: ChemMedChem
Published: June 21, 2015
Showing 1-12 of 13

Last Updated: 09/26/2026